Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Visa to Move European Headquarters to London’s Canary Wharf 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
SEATTLE, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced that it will conduct a conference call on Tuesday, December 8, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss new clinical data from ongoing clinical trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer. The data, which include additional and updated clinical trial data on ONT-380 for the treatment of patients with HER2-positive metastatic breast cancer, as well as an analysis of patients who suffer from central nervous system (CNS) metastases, are slated for presentation during the San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon’s website at www.oncothyreon.com. An archive of the webcast will be available after completion of the discussion and will be posted on the Oncothyreon website.
About Oncothyreon
Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
CONTACT: Investor Relations: Julie Rathbun Rathbun Communications 206-769-9219 [email protected] Media Relations: Kelly France, Ph.D. BrewLife 415-946-1076 [email protected]
